Øystein Bruserud

10.6k total citations · 1 hit paper
350 papers, 8.2k citations indexed

About

Øystein Bruserud is a scholar working on Hematology, Molecular Biology and Immunology. According to data from OpenAlex, Øystein Bruserud has authored 350 papers receiving a total of 8.2k indexed citations (citations by other indexed papers that have themselves been cited), including 224 papers in Hematology, 142 papers in Molecular Biology and 98 papers in Immunology. Recurrent topics in Øystein Bruserud's work include Acute Myeloid Leukemia Research (151 papers), Hematopoietic Stem Cell Transplantation (68 papers) and Immune Cell Function and Interaction (40 papers). Øystein Bruserud is often cited by papers focused on Acute Myeloid Leukemia Research (151 papers), Hematopoietic Stem Cell Transplantation (68 papers) and Immune Cell Function and Interaction (40 papers). Øystein Bruserud collaborates with scholars based in Norway, United States and France. Øystein Bruserud's co-authors include Bjørn Tore Gjertsen, Håkon Reikvam, Kimberley Joanne Hatfield, Elisabeth Ersvær, Anita Ryningen, Randi Hovland, Annette K. Brenner, Astrid Olsnes Kittang, Brynjar Foss and Tor Henrik Anderson Tvedt and has published in prestigious journals such as Cell, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Øystein Bruserud

345 papers receiving 8.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells

2004 546 citations Randi Hovland, Øystein Bruserud et al. profile →

Peers

Countries citing papers authored by Øystein Bruserud

Since Specialization

Citations

This map shows the geographic impact of Øystein Bruserud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Øystein Bruserud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Øystein Bruserud more than expected).

Fields of papers citing papers by Øystein Bruserud

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Øystein Bruserud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Øystein Bruserud. The network helps show where Øystein Bruserud may publish in the future.

Co-authorship network of co-authors of Øystein Bruserud

This figure shows the co-authorship network connecting the top 25 collaborators of Øystein Bruserud. A scholar is included among the top collaborators of Øystein Bruserud based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Øystein Bruserud. Øystein Bruserud is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Acute myeloid leukemia with rare recurring translocations—an overview of the entities included in the international consensus classification 2024 ·Annals of Hematology ·(unknown), (unknown), Øystein Bruserud, Tor Henrik Anderson Tvedt	2
2	Plasma IL-1 and IL-6 Family Cytokines with Soluble Receptor Levels at Diagnosis in Head and Neck Squamous Cell Carcinoma: High Levels Predict Decreased Five-Year Disease-Specific and Overall Survival 2024 ·Cancers ·(unknown), (unknown), (unknown), (unknown), Øystein Bruserud, Tor Henrik Anderson Tvedt, Hans Jørgen Aarstad	1
3	Monocytic Differentiation of Human Acute Myeloid Leukemia Cells: A Proteomic and Phosphoproteomic Comparison of FAB-M4/M5 Patients with and without Nucleophosmin 1 Mutations 2024 ·International Journal of Molecular Sciences ·Frode Selheim, Elise Aasebø, Håkon Reikvam, Øystein Bruserud, Maria Hernandez-Valladares	2
4	Pretransplant Systemic Lipidomic Profiles in Allogeneic Stem Cell Transplant Recipients 2022 ·Cancers ·Kimberley Joanne Hatfield, Øystein Bruserud, Håkon Reikvam	4
5	Patients with Bacterial Sepsis Are Heterogeneous with Regard to Their Systemic Lipidomic Profiles 2022 ·Metabolites ·Knut Anders Mosevoll, (unknown), (unknown), Håkon Reikvam, Øyvind Bruserud, (unknown), Øystein Bruserud, Øystein Wendelbo	7
6	Pure Red Cell Aplasia with Del(20q) Sensitive for Immunosuppressive Treatment 2020 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Randi Hovland, (unknown), Øystein Bruserud, Håkon Reikvam	2
7	The Acute Phase Reaction and Its Prognostic Impact in Patients with Head and Neck Squamous Cell Carcinoma: Single Biomarkers Including C-Reactive Protein Versus Biomarker Profiles 2020 ·Biomedicines ·(unknown), (unknown), (unknown), Øystein Bruserud, (unknown), Hans Jørgen Aarstad, Tor Henrik Anderson Tvedt	13
8	A Kinase Inhibitor with Anti-Pim Kinase Activity is a Potent and Selective Cytotoxic Agent Toward Acute Myeloid Leukemia 2019 ·Molecular Cancer Therapeutics ·(unknown), Reidun Aesöy, Øystein Bruserud, Annette K. Brenner, F Giraud, (unknown), Gro Gausdal, Pascale Moreau, Stein Ove Døskeland, Fabrice Anizon, Lars Herfindal	15
9	Metabolic Serum Profiles for Patients Receiving Allogeneic Stem Cell Transplantation: The Pretransplant Profile Differs for Patients with and without Posttransplant Capillary Leak Syndrome 2015 ·Disease Markers ·(unknown), (unknown), Aymen Ahmed, Kimberley Joanne Hatfield, Øystein Bruserud	12
10	Distinct single cell signal transduction signatures in leukocyte subsets stimulated with khat extract, amphetamine-like cathinone, cathine or norephedrine 2013 ·BMC Pharmacology and Toxicology ·(unknown), Elisabeth Ersvær, (unknown), André Sulen, Håkon Reikvam, Hans Jørgen Aarstad, Anne Christine Johannessen, Olav Karsten Vintermyr, Øystein Bruserud, Bjørn Tore Gjertsen	10
11	The angioregulatory cytokine network in human acute myeloid leukemia – from leukemogenesis via remission induction to stem cell transplantation 2012 ·European Cytokine Network ·Håkon Reikvam, Kimberley Joanne Hatfield, Hanne Fredly, Ina Nepstad, Knut Anders Mosevoll, Øystein Bruserud	46
12	A prospective observational study of the effect of platelet transfusions on levels of platelet-derived cytokines, chemokines and interleukins in acute leukaemia patients with severe chemotherapy-induced cytopenia 2011 ·European Cytokine Network ·Torunn Oveland Apelseth, Tor Hervig, Tore Wentzel‐Larsen, Kjell Petersen, Håkon Reikvam, Øystein Bruserud	17
13	Early pre-engraftment, functional, in vitro responsiveness of T lymphocytes in allotransplanted, acute leukemia patients: proliferation and release of a broad profile of cytokines, possibly predictive of graft-versus-host disease 2010 ·European Cytokine Network ·Knut Liseth, (unknown), (unknown), Øystein Bruserud, Elisabeth Ersvær	12
14	cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation 2006 ·International Journal of Oncology ·Anne M. Øyan, Trond Hellem Bø, Inge Jonassen, Bjørn Tore Gjertsen, Øystein Bruserud, Karl‐Henning Kalland	6
15	TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL 2005 ·Haematologica ·Øystein Bruserud	2
16	Functional Evaluation of Proliferative T Cell Responses in Patients with Severe T Lymphopenia: Characterization of Optimal Culture Conditions and Standardized Activation Signals for a Simple Whole Blood Assay 2003 ·Journal of Hematotherapy & Stem Cell Research ·Øystein Wendelbo, Øystein Bruserud	14
17	Analysis of Acute Myelogenous Leukemia: Preparation of Samples for Genomic and Proteomic Analyses 2002 ·Journal of Hematotherapy & Stem Cell Research ·Bjørn Tore Gjertsen, Anne M. Øyan, Bruz Marzolf, Randi Hovland, Gro Gausdal, Stein Ove Døskeland, Krassen Dimitrov, Allison Golden, Karl‐Henning Kalland, Leroy Hood, Øystein Bruserud	37
18	Effects of Vascular Endothelial Growth Factor on Acute Myelogenous Leukemia Blasts 2001 ·Journal of Hematotherapy & Stem Cell Research ·Brynjar Foss, (unknown), Øystein Bruserud	27
19	In Vitro Culture of Human Acute Myelogenous Leukemia (AML) Cells in Serum-Free Media: Studies of Native AML Blasts and AML Cell Lines 2000 ·Journal of Hematotherapy & Stem Cell Research ·Øystein Bruserud, Bjørn Tore Gjertsen, (unknown)	60
20	Autologous Stem Cell Transplantation As Post-Remission Therapy in Adult Acute Myelogenous Leukemia: Does Platelet Contamination of Peripheral Blood Mobilized Stem Cell Grafts Influence the Risk of Leukemia Relapse? 2000 ·Journal of Hematotherapy & Stem Cell Research ·Øystein Bruserud, Brynjar Foss, Jenny Foss Abrahamsen, Bjørn Tore Gjertsen, Peter Ernst	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact